Integrating antibody-drug conjugates into the management of early breast cancer.

Antibody-drug conjugates (ADCs) are a new class of targeted therapies that have demonstrated clinical benefit across various tumor types and disease stages. In breast cancer, following their success in the metastatic setting, ADCs show improved antitumor activity with potentially reduced systemic toxicity, making them a promising option in the neoadjuvant treatment of early breast cancer. This review examines the evolving role of ADCs in early breast cancer, highlighting emerging clinical trial data, innovative trial designs, and the integration of biomarkers, all aimed at optimizing patient outcomes and personalizing neoadjuvant strategies across different breast cancer subtypes.